Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAK Tujuan penelitian ini adalah untuk melihat perbandingan terapi,toksisitas dan kesintasanhidup. Pasien predominan usia antara 40-60 tahun (81,7%),Karsinoma sel skuamosa (78,8%),diffrensiasis sedang (63,5%), stadium III B (68,3%), dan ukuran tumor > 4 cm (62,5%)Kemoradiasi merupakan terapi yang umumnya dilakukan. Karbogen ( karbon dioksida 2%dan oksigen 98%) + Nikotinamid meningkatkan oksigenisasi tumorABSTRACT The purpose of this study was to compare the therapies, toxicity and survival oflife. Patients are predominantly aged between 40-60 years (81.7%), squamouscell carcinoma (78.8%), diffrensiasis moderate (63.5%), stage III B (68.3%), andtumor size> 4 cm (62.5%) Chemoradiation is a therapy that is generally done.Karbogen (2% carbon dioxide and 98% oxygen) + Nicotinamide improve tumoroxygenation;The purpose of this study was to compare the therapies, toxicity and survival oflife. Patients are predominantly aged between 40-60 years (81.7%), squamouscell carcinoma (78.8%), diffrensiasis moderate (63.5%), stage III B (68.3%), andtumor size> 4 cm (62.5%) Chemoradiation is a therapy that is generally done.Karbogen (2% carbon dioxide and 98% oxygen) + Nicotinamide improve tumoroxygenation;The purpose of this study was to compare the therapies, toxicity and survival oflife. Patients are predominantly aged between 40-60 years (81.7%), squamouscell carcinoma (78.8%), diffrensiasis moderate (63.5%), stage III B (68.3%), andtumor size> 4 cm (62.5%) Chemoradiation is a therapy that is generally done.Karbogen (2% carbon dioxide and 98% oxygen) + Nicotinamide improve tumoroxygenation;The purpose of this study was to compare the therapies, toxicity and survival oflife. Patients are predominantly aged between 40-60 years (81.7%), squamouscell carcinoma (78.8%), diffrensiasis moderate (63.5%), stage III B (68.3%), andtumor size> 4 cm (62.5%) Chemoradiation is a therapy that is generally done.Karbogen (2% carbon dioxide and 98% oxygen) + Nicotinamide improve tumoroxygenation"

"Latar Belakang: Kurkumin diketahui sebagai antiinflamasi, antioksidan, antiproliferatif, dan antiangiogenik, sehingga menjadi salah satu alternatif terapi diabetes tipe 2 dengan menghambat progresifitasnya. Dengan sediaan nanopartikel availibilitasnya semakin meningkat. Penelitian ini dilakukan untuk melihat adanya efek nanokurkumin terhadap komplikasi diabetes melitus khususnya kardiomiopati yang dinilai dengan ekspresi mRNA B-type natriuretic peptide BNP pada jaringan jantung. Metode: Penelitian ini menggunakan jaringan tersimpan dari penelitian yang telah dilakukan sebelumnya. Jaringan kemudian dibuat menjadi cDNA dari sintesis isolasi RNA jaringan jantung tikus. Diabetes tipe 2 pada tikus dibuat dengan menginjeksikan streptozotocin dan nicotinamide. Nanokurkumin diberikan dalam dosis 100mg/kgBB/hari selama 30 hari. Tingkat ekspresi mRNA BNP-45 diukur dengan qRT-PCR dan dihitung dengan metode Livak. Hasil: Terdapat peningkatan ekspresi mRNA BNP-45 pada kelompok DM terhadap kelompok normal. Pemberian nanokurkumin sebanyak 100mg/KgBB selama 30 hari pada kelompok DM NK menghasilkan rasio ekspresi mRNA BNP-45 lebih rendah secara statistik terhadap kelompok DM. Kesimpulan: Nanokurkumin dapat menekan ekspresi mRNA BNP-45 pada jantung tikus yang diinduksi streptozotocin dan nicotinamide pada tingkat dosis 100mg/kgBB/hari selama 30 hari.

---

Background: Curcumin is known as anti inflammatory, antioxidant, antiproliferative, and antiangiogenic. Therefore it is promising to become alternative treatment of type 2 diabetic by inhibiting its progressiveness. From previous study, it was reported that bioavailability of curcumin increases in form of nanoparticles. This study was conducted to see the effect of nanacurcumin on cardiomyopathy assessed by the expression of B type natriuretic peptide BNP mRNA in heart tissue.

Method: This experimental study used stored tissue from previous research. Then the tissue changed to cDNA from RNA isolation synthesis of rats heart tissue. The type 2 diabetic in rat was induced by streptozotocin and nicotinamide. Nanocurcumin was given orally at the dose 100mg kgBW day for 30 days. The expression level of BNP 45 mRNA was measured by qRT PCR and calculated by the Livak method.

Result: There was an increased ratio of expression of BNP 45 mRNA in the DM group against the normal group. Nanocurcumin 100mg KgBB administered orally for 30 days in the DM NK group resulted in a statistically lower ration of BNP 45 mRNA expression than the DM Group.

Conclusion: Nanocurcumin may suppress expression of BNP 45 mRNA in the heart of rats induced streptozotocin and nicotinamide at a dose level of 100 mg kgBW day for 30 days."

"Alyxia reinwardtii dikenal sebagai Pulosari digunakan untuk pengobatan kencing manis dan beberapa penyakit lainnya, memiliki kandungan utama berupa Pulosariosida dan Skopolentin. Penelitian ini dilakukan untuk mengevaluasi efek antidiabetes dan antihiperlipidemia ekstrak etanol dari kulit batang pulosari pada tikus diabetes yang diinduksi kombinasi pakan tinggi lemak, streptozotocin, dan nikotinamid. Untuk mencapai tujuan tersebut, pada penelitian ini menggunakan 24 ekor tikus wistar jantan. Tikus dibagi menjadi enam kelompok (n=4). Kelompok normal dan negatif diberi CMC 0,5%, kelompok positif diberi Metformin dosis 90mg/200g/hari secara oral; dan tiga variasi dosis ekstrak kulit batang pulosari 150mg/kgBB tikus/hari; 300mg/kgBB tikus/hari; 600mg/kgBB tikus/hari secara oral. Tikus diinduksi pakan tinggi lemak (pakan standar : tallow : sukrosa : mentega, 50%:20%:20%:10%) selama 28 hari dan diinduksi nikotinamid (110mg/kgBB) dengan streptozotocin dosis rendah (40mg/kgBB) dua kali injeksi secara intraperitoneal. Kemudian diberikan baik dengan ekstrak kulit batang pulosari dan metformin selama 21 hari. Dosis 300mg/kg dan dosis 600mg/kg ekstrak pulosari melalui uji Anova memberikan perbedaan bermakna pada kadar glukosa darah setelah 21 hari (p<0,05). Ekstrak kulit batang pulosari memiliki potensi yang sama dengan metformin untuk menurunkan kadar glukosa, kolesterol, trigliserida, LDL dan meningkatkan kadar HDL. Berdasarkan hasil penelitian, ekstrak kulit batang pulosari dapat menurunkan dan memperbaiki profil lipid hewan model.

---

Alyxia reinwardtii as known as Pulosari is used traditionally for the treatment of diabetes and some other diseases, the main constituent is Pulosarioside and Scopolentin. The aimed of this study to investigate the antidiabetic effects of extract etanol from bark Alyxia reinwardtii in diabetic rats induced by combination of high-fat diet, streptozotocin, and nicotinamide. To this end, we used 24 Wistar male rats. The rats were divided into six groups (n=4). The normal and negative groups were given 0,5% CMC, positive group was given Metformin dose 90mg/200g/day orally; and three variation dose groups of extract pulosari 150 mg/kg BW rats/day orally; 300 mg/kg BW rats/day orally; 600 mg/kg BW rats/day respectively.

All the treatment rats were induced by the combination of high-fat diet (standard feed: tallow: sucrose: butter, 50%:20%:20%:10%) for 28 days and received nicotinamide (110mg/kg BW) with Low dose STZ (40mg/kg BW) twice by intraperitoneal injection. Then treated with extract pulosari either metformin for 21 days. Doses 300mg/kg BW and 600 mg/kg of extract pulosari after 21 days significantly reduced glucose level (p<0,05). The power of extract pulosari similar to metformin to reduce glucose level, cholesterol level, triglyceride level, LDL level, and increase HDL level. Based on this result, pulosari extract have potency as antidiabetic and improve lipid profiles of animal model."